Drug therapy for ulcerative colitis

被引:29
作者
Xu, Chang-Tai [1 ]
Meng, Shu-Yong [2 ]
Pan, Bo-Rong [3 ]
机构
[1] Fourth Mil Med Univ, Editorial Dept, Xian 710032, Shaanxi Provinc, Peoples R China
[2] Shaanxi Prov Text Hosp, Dept Thorac & Oncol Surg, Xian 710038, Shaanxi Provinc, Peoples R China
[3] Fourth Mil Med Univ, Dept Oncol, Xijing Hosp, Xian 710032, Shaanxi Provinc, Peoples R China
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Ulcerative colitis (UC) is an inflammatory destructive disease of the large intestine occurred usually in the rectum and lower part of the colon as well as the entire colon. Drug therapy is not the only choice for UC treatment and medical management should be as a comprehensive whole. Azulfidine, Asacol, Pentasa, Dipentum, and Rowasa all contain 5-aminosalicylic acid (5-ASA), which is the topical anti-inflammatory ingredient. Pentasa is more commonly used in treating Crohn's ileitis because Pentasa capsules release more 5-ASA into the small intestine than Asacol tablets. Pentasa can also be used for treating mild to moderate UC. Rowasa enemas are safe and effective in treating ulcerative proctitis and proctosigmoiditis. The sulfa-free 5-ASA agents (Asacol, Pentasa, Dipentum and Rowasa) have fewer side effects than sulfa-containing Azulfidine. In UC patients with moderate to severe disease and in patients who failed to respond to 5-ASA compounds, systemic (oral) corticosteroids should be used. Systemic corticosteroids (prednisone, prednisolone, cortisone, etc.) are potent and fast-acting drugs for treating UC, Crohn's ileitis and ileocolitis. Systemic corticosteroids are not effective in maintaining remission in patients with UC. Serious side effects can result from prolonged corticosteroid treatment. To minimize side effects, corticosteroids should be gradually reduced as soon as the disease remission is achieved. In patients with corticosteroid-dependent or unresponsive to corticosteroid treatment, surgery or immunomodulator is considered. Immunomodulators used for treating severe UC include azathioprine/6-MP, methotrexate, and cyclosporine. Integrated traditional Chinese and Western medicine is safe and effective in maintaining remission in patients with UC.
引用
收藏
页码:2311 / 2317
页数:7
相关论文
共 43 条
[1]
Collagenous colitis evolving into ulcerative colitis: A case report and review of the literature [J].
Aqel, B ;
Bishop, M ;
Krishna, M ;
Cangemi, J .
DIGESTIVE DISEASES AND SCIENCES, 2003, 48 (12) :2323-2327
[2]
Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study [J].
Card, T ;
West, J ;
Hubbard, R ;
Logan, RFA .
GUT, 2004, 53 (02) :251-255
[3]
Chen Q, 1999, J Tradit Chin Med, V19, P163
[4]
Chourasia MK, 2003, J PHARM PHARM SCI, V6, P33
[5]
Christodoulou D, 2003, HEPATO-GASTROENTEROL, V50, P1021
[6]
Corominas Hector, 2004, Am J Pharmacogenomics, V4, P1, DOI 10.2165/00129785-200404010-00001
[7]
Outcome of a conservative approach in severe ulcerative colitis [J].
Daperno, M ;
Sostegni, R ;
Scaglione, N ;
Ercole, E ;
Rigazio, C ;
Rocca, R ;
Pera, A .
DIGESTIVE AND LIVER DISEASE, 2004, 36 (01) :21-28
[8]
Diculescu Mircea, 2003, Rom J Gastroenterol, V12, P283
[9]
Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital [J].
Ebinger, M ;
Leidl, R ;
Thomas, S ;
Von Tirpitz, C ;
Reinshagen, M ;
Adler, G ;
König, HH .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (02) :192-199
[10]
The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria [J].
Edmond, LM ;
Hopkins, MJ ;
Magee, EA ;
Cummings, JH .
INFLAMMATORY BOWEL DISEASES, 2003, 9 (01) :10-17